Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Tyra Biosciences, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alphatec Holdings (ATEC), Tyra Bioscience (TYRA) and...

Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Tyra Bioscience today and set a price target of $50.00. Biegler covers the Healthcar...

Tyra Bioscience (TYRA) Gets a Buy from Oppenheimer

Tyra Bioscience, Inc ($TYRA) announced an update on their ongoing clinical study. Tyra Biosciences, Inc (TYRA) is running a first‑in‑human Phase 1 ...

Tyra Biosciences Advances First‑in‑Human TYRA‑430 Trial in FGFR‑Driven Liver and Solid Tumors

Tyra Bioscience, Inc ($TYRA) announced an update on their ongoing clinical study. Tyra Biosciences, Inc is running a first-in-human study called SU...

Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aurora Cannabis (ACB), Eli Lilly & Co (LLY) and Tyra Bioscience (...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aurora Cannabis (ACB), Eli Lilly & Co (LLY) and Tyra Bioscience (TYRA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tyra Bioscience (TYRA), Eli Lilly & Co (LLY) and Per...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TYRA	$26.51	-1.67%	820.62K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TYRA	$26.51	-1.7%	820.62K
3
4
5
6

TYRA

TYRA

Get Tyra Biosciences, Inc. Data in Excel

Get Tyra Biosciences, Inc. Data in Excel